Sanofi sues to protect Lantus

Share this article:

Sanofi has filed a patent lawsuit against Eli Lilly, putting in place a 30-month waiting period for Eli Lilly's Lantus biosimilar.

The lawsuit is not a surprise: Lilly indicated in last week's earnings call that it was expected, because filing its FDA generics review application opened up a notification window, which alerted Sanofi that a potential competitor was on the block. It also put in place a stay that keeps Lilly's drug from progressing through the regulatory pathway.

Sanofi's suit comes with good reason—the diabetes medication earned the company almost $2 billion in third-quarter sales. In 2012, this same drug added just under $7 billion to its global coffers.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.